Actually, the rest of the world shot fireworks when Biden won. They laughed when Trump was president. And while I may not perosnally like Biden, he hasn't done a thing that is grounds for impeachment.
Yes. I’d add that the Bridge Trial was a total blowout and 102 was a grand slam on all points. This data was the original submission with Balance 1/2 under the AA BLA. Also, all three trials were switchover trials that didn’t include the negative adverse events for Fabrazyme/Replagal because those who can handle those ERTs are the only ones in 102s switchovers. >20% drop out of Fabrazyme/Replagal trials from severe adverse events and these are not reflected into the data. If it were a fresh ERT patient trial against 102 vs Replagal/Fabrazyme/Galafold/Placebo…. 102 would’ve blown them out of the water!! They all missed endpoints Vs Placebo.
Latest Comments
LNG Shipping Cannot Keep Up With World LNG Demand
Great read, thanks for sharing.
Microsoft Up 4%+ Despite Missing Q2 Revenue Expectations
Stock looks up to me.
Tuesday Talk: To The Moon With QT!
Good read.
BriaCell Therapeutics' Mission: Destroy Breast Cancer
Excellent read.
Market To Rise 20%+ This Year, Says Wall Street's Biggest Bull
Here's hoping. Last year did us no favors!
7 Reasons Why SurgePays Is Going To Surge
Excellent read. Count me in for $SURG.
Investing In 2023 - The Crucial Events Driving The Markets
Good read, thanks.
Immediate Impeachment Of Joe Biden Should Be The Litmus Test For The Support Of Republicans And All Other American Politicians
Actually, the rest of the world shot fireworks when Biden won. They laughed when Trump was president. And while I may not perosnally like Biden, he hasn't done a thing that is grounds for impeachment.
Protalix BioTherapeutics Well Placed To Advance In 2023
Yes. I’d add that the Bridge Trial was a total blowout and 102 was a grand slam on all points. This data was the original submission with Balance 1/2 under the AA BLA. Also, all three trials were switchover trials that didn’t include the negative adverse events for Fabrazyme/Replagal because those who can handle those ERTs are the only ones in 102s switchovers. >20% drop out of Fabrazyme/Replagal trials from severe adverse events and these are not reflected into the data. If it were a fresh ERT patient trial against 102 vs Replagal/Fabrazyme/Galafold/Placebo…. 102 would’ve blown them out of the water!! They all missed endpoints Vs Placebo.
Stock Market Predictions: 4 Stocks To Watch In 2023
Worth the time to read - highly recommended.